Annogen

🧬Ever wondered what goes into a groundbreaking gene therapy? There are 3 critical components for developing safe and effective cell and gene therapy treatments: ***Therapeutic gene: The targeted DNA sequence to treat a disease. ***Viral vector: The delivery vehicle for the therapeutic gene. ***Promoter: The DNA switch that controls when and where the gene turns on. Despite advancements, many gene therapies face challenges like short-lived expression and off-target effects. Here's where promoters come in. They're the key to ensuring safe, effective therapies. How would a tailored promoter elevate your gene therapy research? #genetherapy #celltherapy #promoters #biotechnology #drugdevelopment

Annogen is the unbeaten expert in unlocking tissue-specific and tailored gene expression by developing bespoke promoters and genomic expression sites. Below we explain the main reasons pharma outsources their gene expression engineering to Annogen. #celltherapy #genetherapy #drugdevelopment #viralvectors

Good morning San Diego! ☀️🐬 With the final day of #BIO2024 here, Annogen will conclude an effective get-together with leading #biopharma, all focused on using our validated in vitro and in vivo #promoters to improve the safety and efficacy of tomorrow's #advancedtherapies. We were blown away by the incredible advancements discussed! Want to learn how Annogen can help improve your gene or cell therapy pipeline? Reach out to Joris van Arensbergen or P. Victor Schut to still meet them today!

📣 Annogen Announces Research Collaboration with Orchard Therapeutics for the Development of CNS-cell Specific Promoters “Building on the safe and effective human promoters we have for our existing programs, we are excited to further establish a leadership position in the field by supporting research for additional CNS-focused cellular targets,” said Frank Thomas, president and CEO of Orchard Therapeutics - U.S.. “This work is critical as we apply our clinically-validated HSC cell therapy platform to more prevalent diseases. We look forward to utilizing Annogen’s SuRE technology to potentially advance certain pre-clinical programs.” “Annogen has gained substantial experience identifying and developing promoters for in vivo gene therapy,” Joris van Arensbergen, CEO of Annogen B.V. adds. “We are very pleased to work with a company in this field that has managed to bring autologous gene therapy through to commercialization in the U.S. and Europe. We are proud to be part of their program and to contribute to the safety and efficacy of certain pre-clinical therapies.” #genetherapy #atmp #bio2024 #biotech

Wows at #ESHG24: Annogen's talented biotinformatician Vartika Bisht presented her pioneering Ph.D. results, a joint program between Annogen and Hubrecht Institute, Developmental Biology and Stem Cell Research, at the ESHG European Society of Human Genetics in Berlin this week. We are proud of her groundbreaking results towards better understanding what causes Hypoplastic left heart syndrome. #HLHS

Our validated off-the-shelf hITA promoter specifically induces transcription upon T cell activation. This system is widely adopted for the development of therapeutic T #celltherapy products. Today Annogen’s senior scientist Daan Peric-Hupkes presents results of our hITA studies at the annual Netherlands Society of Gene and Cell Therapy NVGCT conference. Come learn more from one of our outstanding experts!

It will be hard to miss Annogen this week ✈️ - #ESHG24 Berlin: Vartika Bisht will be presenting her PhD work - #BIO2024 San Diego: Joris van Arensbergen, P. Victor Schut will be partnering - #NVGCT Lunteren: Daan Peric-Hupkes will be presenting our hITA promoter, joined by Michelle van Heck, Martijn Kelder, Ph.D. Please reach out when you wish to meet! #celltherapy #genetherapy Netherlands Society of Gene and Cell Therapy NVGCT Biotechnology Innovation Organization

There are 3 critical components for developing safe and effective cell and gene therapy treatments: 1.    therapeutic gene, 2.    viral vector and 3.    promoter. Short-lived and off-target expression remain a challenge. #Promoters are the next frontier in ensuring safety and effectiveness of #cellandgenetherapy. Annogen supplies bespoke #human promoters enabling expression optimization as well as identification of favourable integration sites for cell engineering. Meet us at #BIO2024 next week to learn about the SuRE™ cell specific or inducible promoters and AIM™ integration site mapping. 

#BIO2024 is around the corner! Looking forward to beautiful San Diego again to catch up with everybody.

Meet Martijn Kelder, Ph.D. At #ASGCT this week!